Optimize drug therapy and monitor patient adherence.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).
Separate serum or plasma from cells within 2 hours of collection. Transport 2 mL serum or plasma. (Min: 1 mL)
CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered.
Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution). Hemolyzed samples.
Olanzapine shows slight interference with high levels of hemolysis in the sample. Noroxycodone causes an analytical interference and impacts the quantitation of Olanzapine.
After separation from cells: Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 1 month
Effective November 15, 2021
|Therapeutic Range:||20-80 ng/mL|
|Toxic:||Greater than or equal to 100 ng/mL|
Olanzapine is an antipsychotic drug indicated for the treatment of depression and bipolar disorder. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. Adverse effects may include dizziness, fatigue, akathisia, postural hypotension, delirium, somnolence, neuroleptic malignant syndrome, hyperglycemia and muscle weakness agitation.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Laboratory Developed Test (LDT)
80342 (Alt code: G0480)
|Component Test Code*||Component Chart Name||LOINC|
- zyprexa blood level
- zyprexa zydis